Anaphore has announced changing of its corporate name to RuiYi. The exercise is a part of the company's shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G-protein coupled receptors (GPCRs). The company also announced new appointments to its management team in Shanghai. The three key members to its management team are expected to guide its GPCR drug discovery efforts.
Dr Chris Song joins as Director of Operations, with more than 20 years of experience in biomedical research and business. Prior to joining RuiYi, he led marketing and sales efforts at OriGene Technologies for its China business initiative.
Dr Shouhua (Josh) Xiao has been appointed as Senior Director of Protein Technology. He has worked in the biotech industry for over 14 years. Prior to joining RuiYi, he was Principal Scientist and led the biologics drug discovery efforts for Oncology at Amgen South San Francisco.
Dr Lei Shi has been appointed as the as Director of Antibody Discovery. He joins RuiYi from Centyrex, an internal venture of Johnson & Johnson, where he was responsible for library technology development and lead generation in the area of immunology and oncology.
RuiYi is also moving its corporate offices to new space in La Jolla, CA. The move will be effective from 15th November 2012.